Aspire Biopharma Holdings, Inc.
ASBP
Rank in Stocks
#28943
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise... Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.
Share Price
$8.80
Last synced: 2026-11-11
Market Cap
$9.13M
Change (1 day)
3.29%
Change (1 year)
-93.08%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aspire Biopharma Holdings, Inc. (ASBP)
Category
Healthcare
Operating Margin for Aspire Biopharma Holdings, Inc. (ASBP)
Operating Margin as of November 2026 TTM: -7,259.92%
According to Aspire Biopharma Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is -7,259.92%. At the end of 2025 the company had an operating margin of -312,016.95%.
Operating Margin history for Aspire Biopharma Holdings, Inc. from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -7,259.92% | -97.67% |
| 2025 | -312,016.95% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -99.97% |
US
|
|
| 33.87% | -100.00% |
US
|
|
| -116.04% | -99.98% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Aspire Biopharma Holdings, Inc.'s operating margin
What is Aspire Biopharma Holdings, Inc.'s operating margin?
Aspire Biopharma Holdings, Inc.'s operating margin is -7,259.92%, as of Nov 2026.
What was Aspire Biopharma Holdings, Inc.'s operating margin in 2025?
In 2025, Aspire Biopharma Holdings, Inc.'s operating margin was -312,016.95%, compared with 0.00% in 2024.
How has Aspire Biopharma Holdings, Inc.'s operating margin changed since 2021?
From 2021 to 2025, Aspire Biopharma Holdings, Inc.'s operating margin was highest in 2024 (0.00%) and lowest in 2025 (-312,016.95%).
How does Aspire Biopharma Holdings, Inc.'s operating margin compare with similar companies?
Aspire Biopharma Holdings, Inc.'s operating margin (-7,259.92%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.